Stem cell metabolic and spectroscopic profiling

Trends in Biotechnology

Volumn 31, Issue 3, 2013, Pages 204-213

  Ramm Sander, Paul ^a   Hau, Peter ^a   Koch, Steffen ^b   Schütze, Karin ^b   Bogdahn, Ulrich ^a   Kalbitzer, Hans Robert ^a   Aigner, Ludwig ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b CellTool GmbH   (Germany)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Mass spectrometry; Metabolomics; Mobile lipids; NMR spectroscopy; Raman microspectroscopy; Stem cells

Indexed keywords

CELL FUNCTIONS; CELL METABOLISM; FUNCTIONAL PROPERTIES; METABOLOMICS; NEURAL STEM CELL; RAMAN MICROSPECTROSCOPY; REGENERATIVE MEDICINE; REPAIR MECHANISM;

MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAMAN SPECTROSCOPY; REPAIR; TISSUE;

STEM CELLS;

CHOLINE; RNA;

CELL FUNCTION; CELL METABOLISM; EMBRYONIC STEM CELL; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; METHODOLOGY; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL LEAST SQUARES REGRESSION; PLURIPOTENT STEM CELL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; STEM CELL; SUPPORT VECTOR MACHINE;

CYTOLOGICAL TECHNIQUES; HUMANS; METABOLOMICS; SPECTRUM ANALYSIS; STEM CELLS;

EID: 84875253392     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.01.008     Document Type: Review

References (89)

1. Sandner B., et al. Neural stem cells for spinal cord repair. Cell Tissue Res. 2012, 349:349-362.
2. Doetsch F., et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999, 97:703-716.
3. Encinas J.M., et al. Division-coupled astrocytic differentiation and age-related depletion of neural stem cells in the adult hippocampus. Cell Stem Cell 2011, 8:566-579.
4. Steffenhagen C., et al. Identity, fate and potential of cells grown as neurospheres: species matters. Stem Cell Rev. 2011, 7:815-835.
5. Paul G., et al. The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS ONE 2012, 7:e35577.
6. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
7. Singh S.K., et al. Cancer stem cells in nervous system tumors. Oncogene 2004, 23:7267-7273.
8. Beier C.P., Beier D. CD133 negative cancer stem cells in glioblastoma. Front. Biosci. (Elite Ed.) 2011, 3:701-710.
9. Dunn W.B., et al. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 2011, 40:387-426.
10. Khoo S.H.G., Al-Rubeai M. Metabolomics as a complementary tool in cell culture. Biotechnol. Appl. Biochem. 2007, 47:71-84.
11. Jain M., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336:1040-1044.
12. Kell D.B., et al. Metabolic footprinting and systems biology: the medium is the message. Nat. Rev. Microbiol. 2005, 3:557-565.
13. Urenjak J., et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 1993, 13:981-989.
14. Ramm P., et al. 1H-NMR spectroscopy of glioblastoma cancer stem cells. Stem Cells Dev. 2011, 20:2189-2195.
15. Griffin J.L., et al. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed. 2002, 15:375-384.
16. Duarte J.M.N., et al. The neurochemical profile quantified by in vivo 1H NMR spectroscopy. Neuroimage 2012, 61:342-362.
17. Mountford C.E., et al. Neurospectroscopy: the past, present and future. Chem. Rev. 2010, 110:3060-3086.
18. Rubakhin S.S., et al. Profiling metabolites and peptides in single cells. Nat. Methods 2011, 8:S20-S29.
19. Downes A., et al. Raman spectroscopy and CARS microscopy of stem cells and their derivatives. J. Raman Spectrosc. 2011, 42:1864-1870.
20. Gronwald W., et al. Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int. 2011, 79:1244-1253.
21. Blankenberg F.G., et al. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 1996, 87:1951-1956.
22. Hakumäki J.M., Kauppinen R.A. 1H NMR visible lipids in the life and death of cells. Trends Biochem. Sci. 2000, 25:357-362.
23. Delikatny E.J., et al. MR-visible lipids and the tumor microenvironment. NMR Biomed. 2011, 24:592-611.
24. Zoula S., et al. Correlation between the occurrence of 1H-MRS lipid signal, necrosis and lipid droplets during C6 rat glioma development. NMR Biomed. 2003, 16:199-212.
25. Barba I., et al. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res. 1999, 59:1861-1868.
26. Quintero M.R., et al. A possible cellular explanation for the NMR-visible mobile lipid (ML) changes in cultured C6 glioma cells with growth. Biochim. Biophys. Acta 2007, 1771:31-44.
27. Manganas L.N., et al. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science 2007, 318:980-985.
28. Hoch J.C., et al. Comment on 'magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain'. Science 2008, 321:640. author reply 640.
29. Friedman S.D. Comment on 'Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain'. Science 2008, 321:640. author reply 640.
30. Jansen J.F.A., et al. Comment on 'Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain'. Science 2008, 321:640. author reply 640.
31. Djurić P.M., et al. Response to Comments on 'Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain'. Science 2008, 321:640.
32. Ramm P., et al. A nuclear magnetic resonance biomarker for neural progenitor cells: is it all neurogenesis?. Stem Cells 2009, 27:420-423.
33. Loewenbrück K.F., et al. Proton MR spectroscopy of neural stem cells: does the proton-NMR peak at 1.28ppm function as a biomarker for cell type or state?. Rejuvenation Res. 2011, 14:371-381.
34. Biebl M., et al. Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain. Neurosci. Lett. 2000, 291:17-20.
35. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999, 12:413-439.
36. Glunde K., et al. Choline metabolism in malignant transformation. Nat. Rev. Cancer 2011, 11:835-848.
37. Hida K., et al. In vivo 1H and 31P NMR spectroscopy of the developing rat brain. Magn. Reson. Med. 1992, 23:31-36.
38. Florian C.L., et al. Regional and developmental variations in metabolite concentration in the rat brain and eye: a study using 1H NMR spectroscopy and high performance liquid chromatography. Neurochem. Res. 1996, 21:1065-1074.
39. Zancanaro C., et al. NMR spectroscopic analysis of rat brain development: in vitro proton and carbon studies of whole tissue and its phospholipid fraction. Dev. Neurosci. 2001, 23:107-112.
40. Kok R.D., et al. Maturation of the human fetal brain as observed by 1H MR spectroscopy. Magn. Reson. Med. 2002, 48:611-616.
41. Girard N., et al. Assessment of normal fetal brain maturation in utero by proton magnetic resonance spectroscopy. Magn. Reson. Med. 2006, 56:768-775.
42. Jansen J.F.A., et al. Stem cell profiling by nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 2006, 56:666-670.
43. Romanska H.M., et al. Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. Neoplasia 2009, 11:1301-1308.
44. Yanes O., et al. Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 2010, 6:411-417.
45. Kulak A., et al. Neurochemical profile of the developing mouse cortex determined by in vivo 1H NMR spectroscopy at 14.1 T and the effect of recurrent anaesthesia. J. Neurochem. 2010, 115:1466-1477.
46. Urenjak J., et al. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 1992, 59:55-61.
47. Bhakoo K.K., Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J. Neurochem. 2000, 74:254-262.
48. Higuera G.A., et al. Patterns of amino acid metabolism by proliferating human mesenchymal stem cells. Tissue Eng. Part A 2012, 18:654-664.
49. Hernández-Benítez R., et al. Taurine stimulates proliferation and promotes neurogenesis of mouse adult cultured neural stem/progenitor cells. Stem Cell Res. 2012, 9:24-34.
50. Wang J., et al. Dependence of mouse embryonic stem cells on threonine catabolism. Science 2009, 325:435-439.
51. Wang J., et al. Metabolic specialization of mouse embryonic stem cells. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:183-193.
52. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
53. Lunt S.Y., Vander Heiden M.G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27:441-464.
54. Simsek T., et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010, 7:380-390.
55. Varum S., et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS ONE 2011, 6:e20914.
56. Panopoulos A.D., et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 2012, 22:168-177.
57. Zhou Y., et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J. Biol. Chem. 2011, 286:32843-32853.
58. Vlashi E., et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16062-16067.
59. Fornazari M., et al. Neuronal differentiation involves a shift from glucose oxidation to fermentation. J. Bioenerg. Biomembr. 2011, 43:531-539.
60. Birket M.J., et al. A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells. J. Cell Sci. 2011, 124:348-358.
61. Folmes C.D.L., et al. Energy metabolism plasticity enables stemness programs. Ann. N. Y. Acad. Sci. 2012, 1254:82-89.
62. Chan J.W., Lieu D.K. Label-free biochemical characterization of stem cells using vibrational spectroscopy. J. Biophotonics 2009, 2:656-668.
63. Downes A., et al. Optical spectroscopy for noninvasive monitoring of stem cell differentiation. J. Biomed. Biotechnol. 2010, 2010:101864.
64. Notingher I., et al. In situ spectroscopic study of nucleic acids in differentiating embryonic stem cells. Vib. Spectrosc. 2004, 35:199-203.
65. Chan J.W., et al. Label-free separation of human embryonic stem cells and their cardiac derivatives using Raman spectroscopy. Anal. Chem. 2009, 81:1324-1331.
66. Ghita A., et al. Cytoplasmic RNA in undifferentiated neural stem cells: a potential label-free Raman spectral marker for assessing the undifferentiated status. Anal. Chem. 2012, 84:3155-3162.
67. Konorov S.O., et al. Evidence of marked glycogen variations in the characteristic Raman signatures of human embryonic stem cells. J. Raman Spectrosc. 2011, 42:1135-1141.
68. Konorov S.O., et al. Absolute quantification of intracellular glycogen content in human embryonic stem cells with Raman microspectroscopy. Anal. Chem. 2011, 83:6254-6258.
69. Marin-Valencia I., et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012, 15:827-837.
70. Maher E.A., et al. Metabolism of [U-(13) C]glucose in human brain tumors in vivo. NMR Biomed. 2012, 25:1234-1244.
71. Dunnett S.B., Rosser A.E. Clinical translation of cell transplantation in the brain. Curr. Opin. Organ Transplant. 2011, 16:632-639.
72. Piccini P., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
73. Freed C.R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
74. Olanow C.W., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
75. Van Laake L.W., et al. Monitoring of cell therapy and assessment of cardiac function using magnetic resonance imaging in a mouse model of myocardial infarction. Nat. Protoc. 2007, 2:2551-2567.
76. Chen L.W., et al. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2011, 10:449-458.
77. Brazzini A., et al. Intraarterial autologous implantation of adult stem cells for patients with Parkinson disease. J. Vasc. Interv. Radiol. 2010, 21:443-451.
78. O'Brien C.A., et al. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16:3113-3120.
79. Zhou B-B.S., et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8:806-823.
80. Morgan R.A., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 2012, 23:1043-1053.
81. Florio T., Barbieri F. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug Discov. Today 2012, 17:1103-1110.
82. Carro M.S., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
83. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24:68-72.
84. Menon L.G., et al. Imaging of human mesenchymal stromal cells: homing to human brain tumors. J. Neurooncol. 2012, 107:257-267.
85. Roger M., et al. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011, 32:2106-2116.
86. Batrakova E.V., et al. Cell-mediated drug delivery. Expert Opin. Drug Deliv. 2011, 8:415-433.
87. Tabatabai G., et al. Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain 2005, 128:2200-2211.
88. Tabatabai G., et al. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach?. Discov. Med. 2011, 11:529-536.
89. Dhermain F.G., et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010, 9:906-920.